Previous 10 | Next 10 |
SOUTH SAN FRANCISCO, Calif., June 23, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced data from its three clinical-stage core inhibitor programs, ...
SOUTH SAN FRANCISCO, Calif., June 09, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced that three abstracts have been accepted for presentation dur...
The chief financial officer of Assembly Biosciences ([[ASMB]] -1.5%) Thomas J. Russo is leaving the company, the company said in a regulatory filing yesterday.Mr. Russo who also served the company as principal financial officer and principal accounting officer has notified the company of...
SOUTH SAN FRANCISCO, Calif., May 24, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced that Lisa Johnson-Pratt, M.D., has joined the company’...
Assembly Biosciences (NASDAQ: ASMB) was featured in a recent equity research report published by ROTH Capital Partners LLC. The report reads, “We are updating our model post the 1Q21 print (no major changes, PT still $13). The stock hit a new all-time low last night, closing at $3.9...
Assembly Biosciences (NASDAQ: ASMB) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “Assembly released its 1Q21 results after the bell, and we had a chance to catch up with management this evening. The new information is incr...
Assembly Biosciences (ASMB): Q1 GAAP EPS of -$0.69 beats by $0.10.Cash, cash equivalents and marketable securities of $214.9MPress Release For further details see: Assembly Biosciences EPS beats by $0.10
SOUTH SAN FRANCISCO, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today reported financial results and recent updates for the first quarter end...
Shares of Assembly Biosciences Inc. (NASDAQ:ASMB) traded today at $4.04, breaking its 52-week low. So far today approximately 2.4 million shares have been exchanged, as compared to an average 30-day volume of 910,000 shares. Assembly Biosciences Inc. (NASDAQ:ASMB) has potential upside of...
Assembly Biosciences Inc. (NASDAQ:ASMB) traded today at a new 52-week low of $4.11. So far today approximately 2.4 million shares have been exchanged, as compared to an average 30-day volume of 1.2 million shares. In the past 52 weeks, Assembly Biosciences Inc. share prices are bracketed...
News, Short Squeeze, Breakout and More Instantly...
Assembly Biosciences Inc. Company Name:
ASMB Stock Symbol:
NASDAQ Market:
Assembly Biosciences Inc. Website:
2024-07-16 14:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
– Data from both ABI-5366 and ABI-1179, novel long-acting helicase-primase inhibitor candidates for recurrent genital herpes, to be presented – – Poster presentation highlights key preclinical data from ABI-5366 supporting its entry into ongoing Phase 1a/b clinical ...
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that the first participant has been dosed in the Phase 1b trial of ABI-4334, a nex...